Daha Önce Tedavi Almış Orta veya Ciddi Romatoid Artrit Hastalarında Sarilumab: NICE Tek Teknoloji Değerlendirmesi’nin Bir Kanıt Değerlendirme Grubu Perspektifi
Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7
In this National Institute for Health and Care (NICE) single technology appraisal of sarilumab (SAR) monotherapy and combination therapy with methotrexate (MTX), SAR was considered to have similar efficacy to other bDMARDs for treating moderate-to-severe RA with inadequate response to cDMARDs or TNFis. SAR was also considered a cost-effective use of National Health Service (NHS) resources versus some or all of its comparators in most considered populations.NICE is an independent organisation res...